Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

3D Metastatic Tumor Model Coupled with Targeted mRNA Immunotherapy for the Effective Management of Breast Cancer Brain Metastases

Descrizione del progetto

Terapia per le metastasi cerebrali da cancro al seno

Le metastasi cerebrali da cancro al seno sono diffuse, ma restano difficili da curare a causa di una diagnosi spesso tardiva e della barriera emato-encefalica. Poiché le terapie convenzionali, quali la chemioterapia e la radioterapia, presentano risultati limitati, sono necessari nuovi trattamenti in grado di raggiungere il cervello. Con il supporto del programma di azioni Marie Skłodowska-Curie, il progetto 3DMETACARE svilupperà una nuova immunoterapia basata sull’mRNA utilizzando nanoparticelle lipidiche. Queste nanoparticelle saranno funzionalizzate con mannosio in superficie per agevolarne la distribuzione attraverso la barriera emato-encefalica. I test saranno condotti su modelli 3D ex vivo di metastasi cerebrali da cancro al seno. Questo approccio interdisciplinare si propone di migliorare i tempi della diagnosi, la valutazione terapeutica e gli esiti del trattamento nel cancro al seno metastatico.

Obiettivo

Breast Cancer Brain Metastases (BC-BM) signifies second most common (30%) among all cancers, majorly effecting women population in the age group 45-69, and almost 40% of BC patients have been diagnosed with BC-BM during BC disease conditions. Conventional BC-BM management (chemo + radiotherapy), despite of progression into loco-regional therapies, have showed major limitations for effective management of BC-BM includes blood–brain barrier (BBB) in brain and substantial diagnosis at preliminary stage of disease. In last two decades several pre-clinical and clinical investigations of BC vaccines based on tumour-associated antigens and tumour-specific antigens approaches but none of the has been approved for either treatment or prevention. However, messenger RNA (mRNA)-based vaccination has the potential to expand the responders using targeted lipid nanoparticles (LNP) to counter challenging tumor microenvironment (TME) and BBB obstacles for metastatic tumour. Thus, 3D-METACARE will be focused on the fabrication of targeted LNP-HER2+mRNA immunotherapy decorated with mannose to effectively target Macrophage mannose receptor 1 with improved permeation through BBB and will target BC-BM. Followed by, robust 3D spheroid (cancer cell lines) and organoid (cancer tissues) model of BC and BC-BM, respectively will be established as effective preclinical models for understanding metastatic behaviour of HER2+ cancer and screening of anticancer therapies. Further, in-vitro 3D models will be conjugated with modified Raman spectroscopy techniques (SERS, CARS and SERM) for quantitative determination of the immunotherapeutic impact (T cell analysis) of LNP-mRNA in the ex-vivo BC and BC-BM models and metabolic activities in the native TME. Overall, 3DMETACARE will be novel interdisciplinary (nanotechnology+bioengineering+photonics) platform converging on current EU’s leading cancer research priorities such as early diagnosis and targeted therapeutics.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2024-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

UNIVERSITY OF LIMERICK
Contributo netto dell'UE
€ 268 568,64
Indirizzo
NATIONAL TECHNOLOGICAL PARK, PLASSEY
- Limerick
Irlanda
Regione
Ireland Southern Mid-West
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato